NATIONAL BLOOD AUTHORITY – ENSURING THE NATIONAL

SUPPLY OF BLOOD &

BLOOD PRODUCTS

John Cahill – NBA CEO 18th AUSTRALIAN & NZ CONFERENCE ON HAEMOPHILIA & RARE BLEEDING DISORDERS 14 October 2017

THE NBA MISSION IS TO ENSURE A SAFE, SECURE,

ADEQUATE & AFFORDABLE BLOOD SUPPLY FOR

AUSTRALIA

TO DO THIS, WE CURRENTLY HAVE 14 CONTRACTS

WITH SUPPLIERS & SERVICE PROVIDERS

WE MANAGE A BUDGET OF ABOUT $1.1 BILLION PA

FOR ALL AUSTRALIAN GOVERNMENTS

ABOUT 15% OF THIS BUDGET ($166m pa) IS SPENT

ON CLOTTING FACTOR PRODUCTS

WHAT DO WE DO?

WE HAVE PLENTY OF ‘GUIDANCE’, INCLUDING

LEGISLATION AND THE NATIONAL BLOOD AGREEMENT

PATIENTS,THEIR REPRESENTATIVES & ADVOCATES

CLINICIANS & SPECIALIST GROUPS

SUPPLIERS & POTENTIAL SUPPLIERS

JURISDICTIONS

GOVERNMENTS

CONSTANT HORIZON SCANNING

DOMESTIC & INTERNATIONAL NETWORKS

EXPECTATIONS

ABDR DATA FOR 2015-16 IS THAT THERE ARE:

ALMOST 6000 PATIENTS WITH BLEEDING DISORDERS

ALMOST 5000 OF THESE PATIENTS HAVE COMMON HEREDITARY BLEEDING DISORDERS

SOME 2300 OF THESE PATIENTS HAVE HAEMOPHILIA A (660 SEVERE PATIENTS) AND

SOME 550 HAVE HAEMOPHILIA B (102 SEVERE PATIENTS)

THIS DATA PROVIDES A COMPELLING FOCUS FOR THE NBA MISSION & AN IMPERATIVE TO HELP GOVERNMENTS DEAL EFFECTIVELY WITH NEW TREATMENT THERAPIES

WHY DO WE DO IT?

HOW DO WE DO IT?

THE NATIONAL BLOOD AGREEMENT CLEARLY

IDENTIFIES A PROCESS FOR EVIDENCE-BASED

EVALUATION OF NEW PRODUCTS & SERVICES

SCHEDULE 4 OF THE AGREEMENT ARTICULATES

THAT PROCESS

HEALTH MINISTERS & THE JURISDICTIONAL BLOOD

COMMITTEE ARE CENTRAL TO THE PROCESS

HOW DO WE DO IT? (THERE’S A LITTLE FRAN IN ALL OF US….)

SCHEDULE 4 EXPLAINS HOW PROPOSALS CAN BE:

INITIATED

EVALUATED

DETERMINED

IMPLEMENTED

CHANGES THAT POTENTIALLY INVOLVE MATERIAL EFFECTS ON CLINICAL CARE AND OUTCOMES, OR ON PRODUCTION, SUPPLY OR COST WILL NORMALLY REQUIRE A HTA

PROCESS REQUIRES PRIOR APPROVAL OF THE PRODUCT BY THE TGA

COOPERATION FROM SUPPLIERS IS CRITICAL

HOW DO WE DO IT?

TENDER FOR EXISTING rFVIII & rFIX PRODUCTS WAS HELD IN 2014, EXPIRES 2019

RFI & STAKEHOLDER CONSULTATION DURING 2017 TO INFORM FUTURE TEMDERING FOR CLOTTING FACTOR PRODUCTS

CONSIDERATION OF CONSULTATION OUTCOMES BY JBC OCURRED MID-2017

DECISION TO PROCEED WITH AN NBA FACILITATED HTA ON EHLs VIA MSAC

INTERIM ARRANGEMENTS WHILE THE HTA PROCEEDS

REFERENCE GROUP ESTABLISHED TO ADVISE THE NBA ON IMPLEMENTATION, INCLUDING AHCDO & HFA

WILL REQUIRE COOPERATION FROM SUPPLIERS

OUTCOMES OF CONSULTATION & NEXT STEPS PUBLISHED ON NBA WEBSITE

WHAT HAVE WE DONE LATELY?

EHL CLOTTING FACTOR PRODUCTS

THERE ARE EXCITING DEVELOPMENTS FOR NEW THERAPIES & TREATMENTS

OUR NEXT SPEAKERS WILL PROVIDE INSIGHT INTO SOME OF THESE DEVELOPMENTS

THE NBA IS VERY AWARE OF THE SIGNIFICANT INTEREST & DEMAND FOR ACCESS AT THE EARLIEST OPPORTUNITY

WE WILL ALL NEED TO CONTINUE TO WORK HARD WITH GOVERNMENTS TO EVALUATE OPPORTUNITIES & ACHIEVE WORLD-CLASS OUTCOMES THAT ARE FUNDED ON THE BASIS OF GOOD EVIDENCE UNDER AUSTRALIA’S NATIONAL SUPPLY ARRANGEMENTS

WHAT’S NEXT?

www.blood.gov.au

Thank you